Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of elagolix intermediate

A technology of elagolix and intermediates, which is applied in the field of drug preparation, can solve problems such as the purification of aryl coupling intermediates, and achieve the effects of reducing the cost of process preparation, not easy to inactivate, and simple operation

Active Publication Date: 2021-03-23
NANJING CHEMPION BIOTECHNOLOGY CO LTD
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] This route has improved the process of multiple steps on the basis of compound patents, but it still cannot solve the problem of purification of aryl coupling intermediates. The residue of metal palladium has brought certain problems to the quality control of raw materials and process stability. challenge

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of elagolix intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] In a 5L three-necked reaction flask, add compound II, 500.0g, compound III, 238.2g, potassium carbonate 484g, and 2-methyl-N1, N3-di-o-tolylbenzene-1,3-diamine 35.3g , stirred and heated to 100°C and refluxed for 10 hours. Thin-layer chromatography showed that the conversion of the raw materials was complete, and the aqueous solution of acetic acid was added dropwise to the reaction solution. Compound I 478g, yield: 95.98%.

Embodiment 2

[0034] In a 2L three-necked reaction flask, sequentially add compound II, 100.00g, compound III, 47.64g, cesium carbonate 228.31g, 2-methyl-N1,N3-di-o-tolylbenzene-1,3-diamine 7.06g , stirred and heated to 60°C and refluxed for 6 hours. Thin-layer chromatography showed that the conversion of the raw materials was complete, and the aqueous solution of acetic acid was added dropwise to the reaction solution. Compound I 90.6g, yield: 91%.

[0035] Catalyst 2-methyl-N1, the synthetic route of N3-di-o-tolylbenzene-1,3-diamine is as follows:

[0036]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of an elagolix intermediate. The preparation method comprises the following steps: in the presence of a catalyst and alkali, heating a compound II and a compound III to 50-100 DEG C in an organic solvent, and carrying out a reflux coupling reaction to obtain a compound I. According to the preparation method of the elagolix intermediate, 2-methyl-N1,N3-di-o-tolylphenyl-1,3-diamine is adopted as a coupling catalyst, so metal residues of a traditional coupling metal catalyst are effectively avoided, the quality of the intermediate is improved, reactionconditions are mild, operation is simple, the catalyst is stable and is not easy to inactivate, anaerobic harsh reaction conditions are not needed, and process preparation cost is greatly reduced.

Description

technical field [0001] The invention belongs to the technical field of medicine preparation, and in particular relates to a preparation method of an elagolix intermediate. Background technique [0002] Elagolix sodium (structural formula V) is an orally administered non-peptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to the GnRH receptor in the pituitary gland conduction. Administration will produce dose-dependent inhibition of luteinizing hormone and follicle-stimulating hormone, and reduce the plasma concentration of ovarian sex hormones, estradiol and progesterone. In July 2018, the drug received FDA approval for the treatment of women with moderate to severe endometriosis pain. It is worth mentioning that elagolix sodium is the first oral therapy approved by the FDA for this indication in ten years; [0003] . [0004] At present, the main synthetic route of elagolix s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/54
CPCC07D239/54
Inventor 陈剑余长泉嵇晓勇
Owner NANJING CHEMPION BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com